Arcturus Therapeutics Holdings (ARCT) Assets (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Assets came in at $245.4 million in Q1 2026, down 26.03% YoY from $331.8 million in Q1 2025, and down 9.49% on a QoQ basis from $271.1 million in Q4 2025.
Analysis
Arcturus Therapeutics Holdings (ARCT) Assets (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of Assets data on file, last reported at $245.4 million in Q1 2026.
- Quarterly Assets fell 26.03% year-over-year to $245.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.4 million (down 26.03% YoY) and the FY2025 annual result came in at $271.1 million, down 21.19% from the prior year.
- Assets retreated to $245.4 million in Q1 2026, from $271.1 million in the prior quarter.
- In the past five years, Assets ranged from a high of $470.9 million in Q1 2023 to a low of $245.4 million in Q1 2026.
- A 5-year average of $363.2 million and a median of $344.1 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets slumped 32.43% — and 2023, when it surged 55.86%.
- Tracing ARCT's Assets over 5 years: stood at $450.4 million in 2022, then slipped by 4.66% to $429.4 million in 2023, then dropped by 19.87% to $344.1 million in 2024, then slipped by 21.19% to $271.1 million in 2025, then fell by 9.49% to $245.4 million in 2026.
- The last three Assets figures came in at $245.4 million (Q1 2026), $271.1 million (Q4 2025), and $282.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | 224.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 224.31 Mn |
| Mar 31, 2026 | 245.41 Mn |
| Dec 31, 2025 | 271.15 Mn |
| Sep 30, 2025 | 282.34 Mn |
| Jun 30, 2025 | 309.27 Mn |
| Mar 31, 2025 | 331.79 Mn |
| Dec 31, 2024 | 344.07 Mn |
| Sep 30, 2024 | 370.65 Mn |
| Jun 30, 2024 | 388.61 Mn |
| Mar 31, 2024 | 418.85 Mn |
| Dec 31, 2023 | 429.40 Mn |
| Sep 30, 2023 | 457.65 Mn |
| Jun 30, 2023 | 430.65 Mn |
| Mar 31, 2023 | 470.86 Mn |
| Dec 31, 2022 | 450.39 Mn |
| Sep 30, 2022 | 293.63 Mn |
| Jun 30, 2022 | 337.01 Mn |
| Mar 31, 2022 | 341.99 Mn |
| Dec 31, 2021 | 392.81 Mn |
| Sep 30, 2021 | 434.54 Mn |